Search the Newsreel

Illumina, Inc. (Nasdaq: ILMN) lifts 2026 outlook after Q2 revenue hits $1.16B

Illumina, Inc. (Nasdaq: ILMN) reported strong Q2 2026 financial results with revenue reaching $1.16 billion, a 9.5% increase from the previous year. This performance led the company to raise its full-year 2026 revenue guidance to $4.60-$4.64 billion and non-GAAP diluted EPS guidance to $5.30-$5.40. …

Illumina Inc. stock outperforms competitors on strong trading day

Illumina Inc. (ILMN) saw its stock rise by 5.27% to $205.09 on Thursday, contributing to its third consecutive day of gains. This performance outpaced the broader market, which also experienced a strong trading day with the S&P 500 Index rising 1.66% and the Dow …

Minas Buenaventura Number of Employees 2026 | Employee Count & Headcount Data

This article provides an in-depth look at Minas Buenaventura's workforce data as of March 2026, sourced from Revelio Labs. It details the company's employee count, growth rates, regional distribution, departmental breakdown, salary information, hiring trends, and employee sentiment. Minas Buenaventura, an Energy and Resources …

Kingboard Laminates Flags Over 200% Surge in First-Half Profit

Why Sanmina (SANM) Is Down 24.7% After Raising 2026 Revenue Outlook On AI Infrastructure Demand

Sanmina (SANM) saw its stock drop 24.7% despite raising its 2026 revenue outlook due to strong AI infrastructure demand. The company reported increased sales and net income in Q3 2026, driven by communications networks, cloud, and AI infrastructure. The raised guidance to $14.0-$14.3 billion …

Liminatus Pharma awaits Nasdaq ruling after saying equity tops $2.5 million threshold

Liminatus Pharma is awaiting a Nasdaq compliance decision regarding its stockholders' equity requirement after its merger with InnocsAI. The company claims its equity now surpasses the $2.5 million threshold needed to maintain its Nasdaq listing. Nasdaq will continue to monitor the company's equity level, …

Liminatus Pharma (NASDAQ: LIMN) cites $2.5M equity in Nasdaq compliance review

Liminatus Pharma, Inc. (LIMN) announced that it believes its stockholders' equity now exceeds $2.5 million following its merger with InnocsAI LLC, awaiting Nasdaq's compliance determination. While the company hopes to meet the equity requirement, Nasdaq will continue monitoring its financial health, and future delisting …

Illumination Acquisition Corp I Revenue Breakdown – NASDAQ:ILLU

This page provides a financial overview of Illumination Acquisition Corp I (ILLU) on Nasdaq. It highlights sections for financials, news, community, technical analysis, and ETFs, allowing users to explore fundamental statistics, statements, dividends, earnings, and segment performance.

Laba Semester I-2026 Naik 15%, Begini Prospek Pertamina Geothermal Energy (PGEO)

Buenaventura Mining (BVN) Earnings Date and Reports 2026 $BVN

Compañía de Minas BuenaventuraA (NYSE:BVN) On Updated 2026 Guidance And The Undervalued Narrative

Illumina (ILMN) Reports Q2 Earnings: What Key Metrics Have to Say

Illumina Fiscal Q2 Earnings, Revenue Rise; 2026 Guidance Revised

Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates

Can Sanmina Keep Winning in the AI Infrastructure Buildout?

AI infrastructure spending continues to reshape the electronics manufacturing landscape. Sanmina Corporation SANM is expanding its manufacturing capabilities to capture rising demand for cloud and accelerated computing platforms. The company's vertically integrated model, automation investments and expanding customer relationships position it to participate in …

ILLUMINA, INC. (ILMN) names Chief Commercial Officer as insider with no holdings

Illumina, Inc. (ILMN) identified Michael C. Sullivan, its Chief Commercial Officer, as a reporting person for insider ownership purposes. This Form 3 filing indicates that Sullivan currently holds no reportable equity, derivative positions, or insider transactions with the company. The disclosure establishes his insider …

How SANM is Turning Revenue Growth Into Higher Profitability

Revenue growth is important, but sustainable shareholder value depends on whether that growth translates into stronger margins, earnings and cash generation. Sanmina Corporation SANM has recently demonstrated that combination through expanding sales and disciplined execution. Demand for cloud and artificial intelligence infrastructure continues to …

Is SANM Stock a Buy After Strong Earnings and Higher AI Demand?

Sanmina Corporation SANM has delivered stronger-than-expected quarterly results while raising its fiscal outlook amid rising demand for artificial intelligence infrastructure. That has renewed investor interest in whether the stock still offers an attractive opportunity. The answer depends on whether the company's earnings momentum, valuation …

Illumina Earnings: What To Look For From ILMN

Illumina Earnings: What To Look For From ILMN Genomics company Illumina (NASDAQ:ILMN) will be announcing earnings results this Thursday after market close. Here's what to expect. Illumina beat analysts' revenue expectations last quarter, reporting revenues of $1.09 billion, up 4.8% year on year. It …

Insights Into Illumina (ILMN) Q2: Wall Street Projections for Key Metrics

In its upcoming report, Illumina (ILMN) is predicted by Wall Street analysts to post quarterly earnings of $1.23 per share, reflecting an increase of 3.4% compared to the same period last year. Revenues are forecasted to be $1.12 billion, representing a year-over-year increase of …

Illumina Inc (ILMN) Valuation: PE, PB & Fair Value Analysis

Illumina Inc (ILMN) currently holds a valuation score of 9.61, positioning it 8th out of 199 companies in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 34.86, which is slightly below its recent high but significantly above its recent low. The …

Illumina Inc (ILMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Illumina Inc (ILMN), detailing its current price momentum score of 3.44 and suggesting it's suitable for range-bound swing trading between resistance at $203.15 and support at $178.79. It evaluates various technical indicators like MACD, RSI, and moving …

Illumina, Inc. Revenue Breakdown – LSX:927079

This article provides a revenue breakdown for Illumina, Inc. (LSX:927079), detailing its performance in the last fiscal year. The company generated 3.70 billion EUR, with its Core Illumina - Consumables segment being the top contributor at 2.75 billion EUR. Geographically, the United States was …

SANM Q2 Deep Dive: AI Demand and Integration Drive Growth, Guidance Signals Mixed Outlook

SANM Q2 Deep Dive: AI Demand and Integration Drive Growth, Guidance Signals Mixed Outlook Electronics manufacturing services company Sanmina (NASDAQ:SANM) reported Q2 CY2026 results beating Wall Street's revenue expectations , with sales up 69.7% year on year to $3.46 billion. On the other hand, …

GUIDANCE: (SANM) Sanmina Corporation Expects Q4 Adjusted EPS Range $3.05 - $3.35

Sanmina Corporation (SANM) has released its guidance for the fourth quarter, projecting an adjusted EPS range of $3.05 to $3.35. This report offers investors key financial expectations for the company's upcoming performance.

PT Pertamina Geothermal Energy Tbk Revenue Breakdown – IDX:PGEO

Illumina CIO: In the AI Era, ‘Tech Leaders Are in the Driver’s Seat’

Illumina CIO Mark Field asserts that technology leaders are currently making critical decisions as AI transforms industries, positioning them in the "driver's seat." He emphasizes the importance of reimagining IT organizations around AI, fostering AI fluency within teams, and transitioning IT from an order-taker …

SANMINA CORP : JP MORGAN CUTS TARGET PRICE TO $260 FROM $275

JP Morgan has cut its target price for SANMINA CORP (SANM.O) from $275 to $260. This news was reported by Reuters on July 28, 2026. The article specifically highlights this change in the financial

Illumina Inc (ILMN) finishes latest week with a 42.9% 12-week climb

The diagnostics and research stock remains in an active weekly trend, but lighter volume and modest Relative Strength keep the setup mixed.

Liminatus Pharma Faces Nasdaq Delisting Risk, Plans Reverse Split

Liminatus Pharma (LIMN) is facing delisting from Nasdaq due to failing to meet the minimum bid price requirement. The company was notified in January 2026 and, after a hearing in June, was informed in July 2026 that it still had not regained compliance and …

JPMorgan Chase & Co. Issues Pessimistic Forecast for Sanmina (NASDAQ:SANM) Stock Price

JPMorgan Chase & Co. has lowered its price target for Sanmina (NASDAQ:SANM) to $260 from $275, while maintaining a neutral rating, despite the company reporting strong fiscal third-quarter results. Sanmina exceeded analyst expectations for both EPS and revenue and provided optimistic fiscal 2026 guidance. …

Sanmina Q3 Earnings Call Signals AI Infrastructure Growth Strategy

Sanmina Corporation SANM entered its third-quarter fiscal 2026 earnings call with a focus on expanding its role in artificial intelligence (AI) infrastructure manufacturing. Management highlighted stronger demand, new customer wins and progress in integrating ZT Systems. The discussion centered on how Sanmina is positioning …

SANM Q3 Earnings Beat Estimates on AI Demand, Strong Execution

Sanmina Corporation SANM reported strong third-quarter fiscal 2026 results, with adjusted earnings and revenues surpassing the Zacks Consensus Estimate. Non-GAAP earnings came in at $3.31 per share, up 116% year over year and ahead of the consensus estimate of $2.78 by 19.06%. Revenues of …

Standard BioTools Announces Sale of Mass Cytometry Business and Illumina's Buyout of Contingent Payments to Advance Merger with Treeline Biosciences

Standard BioTools (NASDAQ: LAB) has announced key updates to advance its merger with Treeline Biosciences. The company is selling its Mass Cytometry business to Multiplex Bio for up to $10 million, ensuring continuity of its CyTOF and Hyperion product lines. Additionally, Standard BioTools received …

Standard BioTools Sells Mass Cytometry Business and Secures $30 Million Illumina Buyout Ahead of Treeline Merger

Standard BioTools Inc. has announced strategic transactions aimed at streamlining its business and bolstering its balance sheet before its planned merger with Treeline Biosciences. The company sold its Mass Cytometry business to Multiplex Bio for up to $10 million, secured a $30 million buyout …

Sanmina Corp Lobbyists, 2006

This article from OpenSecrets details the lobbying activities of Sanmina Corp in 2006. It identifies one named lobbyist, Charles Grainger of CG Technologies, who worked for Sanmina-SCI Corp. The report also highlights that there were no "revolving door" lobbyists who previously worked in the …